Search Legislation

Advanced Search

Council Regulation (EEC) No 2377/90 (repealed)Show full title

Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (repealed)

Help about what version

What Version

Help about advanced features

Advanced Features

More Resources

Revised version PDFs

Help about UK-EU Regulation

Legislation originating from the EU

When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.

Close

This item of legislation originated from the EU

Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).

Status:

Point in time view as at 19/11/2005.

Changes to legislation:

There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX III . Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

[F1ANNEX III U.K. LIST OF PHARMACOLOGICALLY ACTIVE SUBSTANCES USED IN VETERINARY MEDICINAL PRODUCTS FOR WHICH PROVISIONAL MAXIMUM RESIDUE LIMITS HAVE BEEN FIXED

Textual Amendments

1. Anti-infectious agents U.K.

1.1. Chemotheurapeutics U.K.

1.1.2. Benzenesulphonamides U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Clorsulon Clorsulon Bovine 50 μg/kg Muscle Provisional MRLs expire on 1 January 2000
150 μg/kg Liver
400 μg/kg Kidney

1.2. Antibiotics U.K.

1.2.1. Beta-lactamase inhibitors U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Clavulanic acid Clavulanic acid Bovine, ovine 200 μg/kg Milk [F2Provisional MRLs expire on 1 July 2001]
Bovine, ovine, porcine 200 μg/kg Muscle
200 μg/kg Fat
200 μg/kg Liver
200 μg/kg Kidney

Textual Amendments

1.2.2. Macrolides U.K.
a

[F3Provisional MRLs expire on 1 July 2006 .

b

Not for use in animals from which eggs are produced for human consumption.]

Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
[F4Acetylisovaleryltylosin Sum of acetylisovaleryltylosin and 3-O-acetyltylosin Porcine 100 μg/kg Muscle Provisional MRLs expire on 1.7.2001
100 μg/kg Skin and fat
100 μg/kg Liver
100 μg/kg Kidney]
[F3Acetylisovaleryltylosin a Sum of acetyl-isovaleryltylosin and 3-O-acetyltylosin Poultry b 50 μg/kg Skin and fat
50 μg/kg Liver ]
Erythromycin MRLs apply to all microbiological active residues expressed as erythromycin equivalent Bovine, ovine 40 μg/kg Milk Provisional MRLs expire on 1 June 2000
Bovine, ovine, porcine, poultry 400 μg/kg Muscle
400 μg/kg Fat
400 μg/kg Liver
400 μg/kg Kidney
Poultry 200 μg/kg Eggs
Josamycin Josamycin Chicken 200 μg/kg Muscle [F5Provisional MRLs expire on 1.7.2002]
200 μg/kg Fat
200 μg/kg Liver
400 μg/kg Kidney
200 μg/kg Eggs
[F6 Sum of the microbiologically active metabolites, expressed as josamycin Porcine 200 μg/kg Muscle Provisional MRLs expire on 1.7.2002
200 μg/kg Skin and fat
200 μg/kg Liver
400 μg/kg Kidney]
[F7Tilmicosin Tilmicosin Bovine 40 μg/kg Milk Provisional MRLs expire on 1.1.2001]
[F8Tulathromycin (2R,3S,4R,5R,8R,10R,11R,12S, 13S,14R)-2- ethyl-3,4,10,13-tetrahydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa- 6-azacyclopent-decan-15-one expressed as tulathromycin equivalents Bovine 100 μg/kg Fat Provisional MRLs expire on 1 July 2004 ; not for use in animals from which milk is produced for human consumption
3 000  μg/kg Liver
3 000  μg/kg Kidney
Porcine 100 μg/kg Skin and fat Provisional MRLs expire on 1 July 2004
3 000  μg/kg Liver
3 000  μg/kg Kidney]

Textual Amendments

[F91.2.4. Cephalosporins U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Cefacetrile Cefacetrile Bovine 125 μg/kg Milk

[F10Provisional MRLs expire on 1.1.2002]

For intrammamary use only

[F11Cefalonium Cefalonium Bovine 10 μg/kg Milk [F12Provisional MRLs expire on 1.1.2003] ]
[F13Cefoperazone Cefoperazone Bovine 50 μg/kg Milk Provisional MRLs expire on 1 January 2001]
[F14Cefquinome Cefquinome Porcine 50 μg/kg Muscle Provisional MRLs expire on 1.1.2000
50 μg/kg Skin + fat
100 μg/kg Liver
200 μg/kg Kidney]
Cephapirin Sum of cephapirin and desacetylcephapirin Bovine 50 μg/kg Muscle Provisional MRLs expire on 1.1.2001
50 μg/kg Fat
50 μg/kg Liver
100 μg/kg Kidney
10 μg/kg Milk]

Textual Amendments

Textual Amendments

1.2.5. Aminoglycosides U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Aminosidine Aminosidine Bovine, porcine, rabbits, chicken 500 μg/kg Muscle Provisional MRLs expire on 1 July 2000
1 500  μg/kg Liver
1 500  μg/kg Kidney
Apramycin Apramycin Bovine 1 000  μg/kg Muscle Provisional MRLs expire on 1 July 1999
For use in non-lactating cattle only 1 000  μg/kg Fat
10 000  μg/kg Liver
20 000  μg/kg Kidney
Porcine 1 000  μg/kg Muscle
1 000  μg/kg Skin and fat
1 000  μg/kg Liver
5 000  μg/kg Kidney
[F15Dihydrostreptomycin Dihydrostreptomycin Bovine, ovine 500 μg/kg Muscle Provisional MRLs expire on 1.6.2002
500 μg/kg Fat
500 μg/kg Liver
1 000  μg/kg Kidney
200 μg/kg Milk
Porcine 500 μg/kg Muscle
500 μg/kg Skin and fat
500 μg/kg Liver
1 000  μg/kg Kidney
Gentamicin Gentamicin Bovine 100 μg/kg Milk Provisional MRLs expire on 1.6.2002
Bovine, porcine 50 μg/kg Muscle
50 μg/kg Fat
200 μg/kg Liver
750 μg/kg Kidney]
[F16Kanamycin Kanamycin Rabbits 100 μg/kg Muscle [F17Provisional MRLs expire on 1.1.2004]
100 μg/kg Fat
600 μg/kg Liver
2 500  μg/kg Kidney
Bovine, ovine 100 μg/kg Muscle
100 μg/kg Fat
600 μg/kg Liver
2 500  μg/kg Kidney
150 μg/kg Milk
Porcine, chicken 100 μg/kg Muscle
100 μg/kg Skin + fat
600 μg/kg Liver
2 500  μg/kg Kidney]
[F15Neomycin (including framycetin) Neomycin B Bovine, porcine, chicken 500 μg/kg Muscle Provisional MRLs expire on 1.6.2002
500 μg/kg Fat
500 μg/kg Liver
5 000  μg/kg Kidney
Bovine 500 μg/kg Milk
Chicken 500 μg/kg Eggs]
Spectinomycin Spectinomycin Bovine 200 μg/kg Milk Provisional MRLs expire on 1 July 2000
Bovine, porcine, poultry 300 μg/kg Muscle
500 μg/kg Fat
2 000  μg/kg Liver
5 000  μg/kg Kidney
[F11

Ovine

Not for use in animals from which milk is produced for human consumption

300 μg/kg Muscle Provisional MRLs expire on 1.1.2002
500 μg/kg Fat
2 000  μg/kg Liver
5 000  μg/kg Kidney
Chicken 200 μg/kg Eggs]
[F15Streptomycin Streptomycin Bovine, ovine 500 μg/kg Muscle Provisional MRLs expire on 1.6.2002
500 μg/kg Fat
500 μg/kg Liver
1 000  μg/kg Kidney
200 μg/kg Milk
Porcine 500 μg/kg Muscle
500 μg/kg Skin and fat
500 μg/kg Liver
1 000  μg/kg Kidney]

Textual Amendments

1.2.6. Quinolones U.K.
a

[F18Provisional MRLs expire 1 January 2006 .

b

Not for use in animals from which milk is produced for human consumption.]

Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
[F6Danofloxacin Danofloxacin Porcine 100 μg/kg Muscle Provisional MRLs expire on 1.1.2000
50 μg/kg Skin and fat
200 μg/kg Liver
200 μg/kg Kidney]
Decoquinate Decoquinate Bovine, ovine 500 μg/kg Muscle Provisional MRLs expire on 1 July 2000
500 μg/kg Fat
500 μg/kg Liver
500 μg/kg Kidney
[F19Difloxacin Difloxacin

Bovine

Not for use in animals from which milk is produced for human consumption

400 μg/kg Muscle Provisional MRLs expire on 1.1.2001
100 μg/kg Fat
1 400 μg/kg Liver
800 μg/kg Kidney
Porcine 400 μg/kg Muscle
100 μg/kg Skin and fat
800 μg/kg Liver
800 μg/kg Kidney]
Enrofloxacin Sum of enrofloxacin and ciprofloxacin Ovine 100 μg/kg Muscle Provisional MRLs expire on 1 July 1999
100 μg/kg Fat
300 μg/kg Liver
200 μg/kg Kidney
Flumequine Flumequine Bovine, ovine, porcine, chicken 50 μg/kg Muscle Provisional MRLs expire on 1 January 2000
50 μg/kg Fat or skin and fat
100 μg/kg Liver
300 μg/kg Kidney
Salmonidae 150 μg/kg Muscle and skin
Marbofloxacin Marbofloxacin Bovine 150 μg/kg Muscle Provisional MRLs expire on 1 July 2000
50 μg/kg Fat
150 μg/kg Liver
150 μg/kg Kidney
75 μg/kg Milk
Porcine 150 μg/kg Muscle
50 μg/kg Skin and fat
150 μg/kg Liver
150 μg/kg Kidney
[F9 [F20Oxolinic acid a Oxolinic acid Bovine b 100 µg/kg Muscle
50 µg/kg Fat
150 µg/kg Liver
150 µg/kg Kidney]
Porcine 100 μg/kg Muscle
50 μg/kg Skin + fat
150 μg/kg Liver
150 μg/kg Kidney
Chicken 100 μg/kg Muscle
50 μg/kg Skin + fat
150 μg/kg Liver
150 μg/kg Kidney
50 μg/kg Eggs
Fin fish 300 μg/kg Muscle and skin in natural proportions]

Textual Amendments

1.2.9. Polymyxins U.K.
Phamarcologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Colistin Colistin Bovine, ovine 50 μg/kg Milk [F5Provisional MRLs expire on 1.7.2002]
Bovine, ovine, porcine, chicken, rabbits 150 μg/kg Muscle
150 μg/kg Fat
150 μg/kg Liver
200 μg/kg Kidney
Chicken 300 μg/kg Eggs
1.2.10. Penicillins U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
[F9Nafcillin Nafcillin Bovine 300 μg/kg Muscle Provisional MRLs expire on 1.1.2001
300 μg/kg Fat
300 μg/kg Liver
300 μg/kg Kidney
30 μg/kg Milk]
Penethamate Benzylpenicillin Ovine 50 μg/kg Muscle Provisional MRLs expire on 1 January 2000
50 μg/kg Fat
50 μg/kg Liver
50 μg/kg Kidney
4 μg/kg Milk
Porcine 50 μg/kg Muscle
50 μg/kg Fat
50 μg/kg Liver
50 μg/kg Kidney
1.2.11. Florfenicol and related compounds U.K.
a

[F21Provisional MRLs expire on 1 January 2007 .]

Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Florfenicol Sum of florfenicol and its metabolites measured as florfenicol-amine Fish 1 000  μg/kg Muscle and skin in natural proportions Provisional MRLs expire on 1 July 2001
[F9Thiamphenicol Thiamphenicol Ovine 50 μg/kg Muscle Provisional MRLs expire on 1.1.2001
50 μg/kg Fat
50 μg/kg Liver
50 μg/kg Kidney
Porcine 50 μg/kg Muscle
50 μg/kg Skin + fat
50 μg/kg Liver
50 μg/kg Kidney
Fin fish 50 μg/kg Muscle and skin in natural proportions]
[F21Thiamphenicol a Thiamphenicol Porcine 50  μg/kg Muscle
50  μg/kg Skin + fat
50  μg/kg Liver
50  μg/kg Kidney ]

Textual Amendments

[F61.2.12. Polypeptides U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Bacitracin Bacitracin Bovine 150 μg/kg Milk Provisional MRLs expire on 1.7.2001]
[F91.2.13. Lincosamides U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Lincomycin Lincomycin Ovine 100 μg/kg Muscle Provisional MRLs expire on 1.1.2001
50 μg/kg Fat
500 μg/kg Liver
1 500 μg/kg Kidney
150 μg/kg Milk
Porcine 100 μg/kg Muscle
50 μg/kg Skin + fat
500 μg/kg Liver
1 500 μg/kg Kidney
Chicken 100 μg/kg Muscle
50 μg/kg Skin + fat
500 μg/kg Liver
1 500 μg/kg Kidney
50 μg/kg Eggs
[F6Pirlimycin Pirlimycin Bovine 100 μg/kg Muscle Provisional MRLs expire on 1.7.2000
100 μg/kg Fat
1 000 μg/kg Liver
400 μg/kg Kidney
100 μg/kg Milk] ]
[F111.2.14. Pleuromutilines U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Tiamulin Sum of metabolites that may be hydrolysed to 8-a-hydroxymutilin Turkey 100 μg/kg Muscle Provisional MRLs expire on 1.7.2001
100 μg/kg Skin and fat
300 μg/kg Liver]

2. Antiparasitic agents U.K.

2.1. Agents acting against endoparasites U.K.

[F192.1.1. Phenol derivatives including salicylanides U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Oxyclozanide Oxyclozanide Bovine 20 μg/kg Muscle [F5Provisional MRLs expire on 1.7.2002]
20 μg/kg Fat
500 μg/kg Liver
100 μg/kg Kidney
10 μg/kg Milk
Ovine 20 μg/kg Muscle
20 μg/kg Fat
500 μg/kg Liver
100 μg/kg Kidney]
2.1.2. Benzimidazoles and pro-benzimidazoles U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Albendazole sulphoxide Sum of albendazole, albendazole sulphoxide, albendazole sulphone, and albendazole 2-amino sulphone, expressed as albendazole Bovine, ovine 100 μg/kg Milk Provisional MRLs expire on 1 January 2000
Bovine, ovine, pheasant 100 μg/kg Muscle
100 μg/kg Fat
1 000  μg/kg Liver
500 μg/kg Kidney
[F11Mebendazole Sum of mebendazole methyl (5-(1-hidroxy, 1-phenyl) methyl-1H-benzimidazol-2-yl) carbamate and (2-amino-1H-benzimidazol-5-yl) phenylmethanone, expressed as mebendazole equivalents

Ovine, caprine, equidae

Not for use in animals from which milk is produced for human consumption

60 μg/kg Muscle Provisional MRLs expire on 1.1.2002
60 μg/kg Fat
400 μg/kg Liver
60 μg/kg Kidney]
Netobimin Sum of netobimin and albendazole and metabolites of albendazole measured as 2-amino- benzimidazole sulphone Bovine, ovine, caprine 100 μg/kg Muscle Provisional MRLs expire on 31 July 1999
100 μg/kg Fat
1 000  μg/kg Liver
500 μg/kg Kidney
100 μg/kg Milk
[F192.1.3. Tetrahydropyrimides U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Morantel Sum of residues which may be hydrolysed to N-Methyl-1,3-propanediamine and expressed as morantel equivalents Bovine, ovine 100 μg/kg Muscle [F12Provisional MRLs expire on 1.7.2003]
100 μg/kg Fat
800 μg/kg Liver
200 μg/kg Kidney
100 μg/kg Milk
Porcine 100 μg/kg Muscle
100 μg/kg Skin and fat
800 μg/kg Liver
200 μg/kg Kidney]
[F72.1.5. Piperazine derivatives U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Piperazine Piperazine Porcine 400 μg/kg Muscle [F22Provisional MRLs expire on 1.7.2003]
800 μg/kg Skin and fat
2 000  μg/kg Liver
1 000  μg/kg Kidney
Chicken 2 000  μg/kg Eggs]

Textual Amendments

[F112.1.6. Salicylanilides U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Rafoxanide Rafoxanide

Bovine

Not for use in animals from which milk is produced for human consumption

30 μg/kg Muscle Provisional MRLs expire on 1.7.2001
30 μg/kg Fat
10 μg/kg Liver
40 μg/kg Kidney

Ovine

Not for use in animals from which milk is produced for human consumption

100 μg/kg Muscle
250 μg/kg Fat
150 μg/kg Liver
150 μg/kg Kidney]

2.2. Agents acting against ectoparasites U.K.

2.2.1. Formamidines U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Amitraz Sum of amitraz and all metabolites containing the 2,4-DMA moeity, expressed as amitraz Bees 200 μg/kg Honey Provisional MRLs expire on 1 July 1999
2.2.2. Iminophenyl thiazolidine derivative U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Cymiazole Cymiazole Bees 1 000  μg/kg Honey [F23Provisional MRLs expire on 1.7.2001]

Textual Amendments

2.2.3. Pyretrin and pyrethroids U.K.
a

[F24Provisional MRLs expire on 1 July 2006 .]

Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Cyfluthrin Cyfluthrin Bovine 10 μg/kg Muscle Provisional MRLs expire on 1 January 2001
50 μg/kg Fat
10 μg/kg Liver
10 μg/kg Kidney
20 μg/kg Milk
Further provisions in Council Directive 94/29/EC are to be observed ( OJ L 189, 23.7.1994, p. 67 )
[F14Alphacypermethrin Cypermethrin (sum of isomers) Bovine, ovine 20 μg/kg Muscle

[F25Provisional MRLs expire on 1.7.2003

Further provisions in Directive 93/57/EC are to be observed]

200 μg/kg Fat
20 μg/kg Liver
20 μg/kg Kidney
20 μg/kg

Milk

[F26Further provisions in Council Directive 93/57/EC ( OJ L 211, 23.8.1992, p. 1 ) are to be observed]

Chicken 50 μg/kg Muscle
50 μg/kg Skin + fat
50 μg/kg Liver
50 μg/kg Kidney
50 μg/kg Eggs
[F25Cypermethrin Cypermethrin (sum of isomers) Bovine 20 μg/kg Muscle

Provisional MRLs expire on 1.7.2003

Further provisions in Directive 93/57/EC are to be observed

200 μg/kg Fat
20 μg/kg Liver
20 μg/kg Kidney
20 μg/kg Milk
Cypermethrin (sum of isomers) Ovine 20 μg/kg Muscle

Provisional MRLs expire on 1.7.2003

Not for use in animals from which milk is produced for human consumption

200 μg/kg Fat
20 μg/kg Liver
20 μg/kg Kidney]
Porcine 20 μg/kg Muscle
200 μg/kg Skin + fat
20 μg/kg Liver
20 μg/kg Kidney
Chicken 50 μg/kg Muscle
50 μg/kg Skin + fat
50 μg/kg Liver
50 μg/kg Kidney
50 μg/kg Eggs
Salmonidae 50 μg/kg Muscle and skin in natural proportions [F27Provisional MRLs expire on 1.7.2003] ]
[F28Deltamethrin Deltamethrin Bovine 10 μg/kg Muscle Provisional MRLs expire on 1 July 2001
50 μg/kg Fat
10 μg/kg Liver
10 μg/kg Kidney
20 μg/kg Milk

Ovine

Not for use in animals from which milk is produced for human consumption

10 μg/kg Muscle
50 μg/kg Fat
10 μg/kg Liver
10 μg/kg Kidney
Chicken 10 μg/kg Muscle [F29Provisional MRLs expire on 1.7.2003]
50 μg/kg Skin + fat
10 μg/kg Liver
10 μg/kg Kidney
50 μg/kg Eggs
[F30 Fin fish 10 μg/kg Muscle and skin in natural proportions Provisional MRLs expire on 1.1.2002] ]
[F31Fenvalerate a Fenvalerate (sum of RR, SS, RS and SR isomers) Bovine 25 μg/kg Muscle
250 μg/kg Fat
25 μg/kg Liver
25 μg/kg Kidney
40 μg/kg Milk]
[F10Permethrin Permethrin (sum of isomers) Chicken, porcine 50 μg/kg Muscle Provisional MRLs expire on 1.1.2003
500 μg/kg Skin and fat
50 μg/kg Liver
50 μg/kg Kidney
Bovine, caprine 50 μg/kg Muscle Provisional MRLs expire on 1.1.2003
500 μg/kg Fat
50 μg/kg Liver
50 μg/kg Kidney
50 μg/kg Milk Further provisions in Commission Directive 98/82/EC are to be observed ( OJ L 290, 29.10.1998, p. 25 )
Chicken 50 μg/kg Eggs Provisional MRLs expire on 1.1.2003]

Textual Amendments

2.2.4. Organophosphates U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Azamethiphos Azamethiphos Salmonidae 100 μg/kg Muscle and skin in natural proportions Provisional MRLs expire on 1 June 1999
[F16Coumafos Coumafos Bees 100 μg/kg Honey Provisional MRLs expire on 1.7.2001]
[F32Phoxim Phoxim Porcine 20 μg/kg Muscle Provisional MRLs expire on 1 January 2001
700 μg/kg Skin and fat
20 μg/kg Liver
20 μg/kg Kidney
[F33Ovine 50 μg/kg Muscle Provisional MRLs expire on 1.7.2001 ; not for use in animals from which milk is produced for human consumption
400 μg/kg Fat
50 μg/kg Kidney]
[F34Chicken 50 μg/kg Muscle Provisional MRLs expire on 1.7.2005 .
550 μg/kg Skin and fat
25 μg/kg Liver
50 μg/kg Kidney
60 μg/kg Eggs] ]
[F11Propetamphos Sum of residues of propetamphos and desisopropyl-propetamphos

Ovine

Not for use in animals from which milk is produced for human consumption

90 μg/kg Fat Provisional MRLs expire on 1.1.2001
90 μg/kg Kidney]

Textual Amendments

2.2.5. Acyl urea derivates U.K.
a

[F35Provisional MRLs expire on 1.1.2007 .

b

Not for use in animals from which milk is produced for human consumption.]

Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Teflubenzuron Teflubenzuron Salmonidae 500 μg/kg Muscle and skin in natural proportions Provisional MRLs expire on 1 July 1999
[F19Diflubenzuron Diflubenzuron Salmonidae 1 000 μg/kg Muscle and skin in natural proportions Provisional MRLs expire on 1.7.2000]
[F35Fluazuron a Fluazuron Bovine b 200 μg/kg Muscle
7 000  μg/kg Fat
500 μg/kg Liver
500 μg/kg Kidney ]

Textual Amendments

[F362.2.6. Pyrimidines derivatives U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Dicyclanil Sum of dicyclanil and 2,4,6-triamino-pyrimidine-5-carbonitrile Ovine 200 μg/kg Muscle

Provisional MRLs expire on 1 July 2000 ;

Not for use in animals from which milk is produced for human consumption

50 μg/kg Fat
400 μg/kg Liver
400 μg/kg Kidney]

Textual Amendments

[F72.2.7. Triazine derivatives U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Cyromazine Cyromazine Ovine 300 μg/kg Muscle

Provisional MRLs expire on 1.7.2001

Not for use in animals from which milk is produced for human consumption

300 μg/kg Fat
300 μg/kg Liver
300 μg/kg Kidney]

2.3. Agents acting against endo- and ectoparasites U.K.

2.3.1. Avermectins U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
[F11Abamectin Avermectin B1a Ovine 20 μg/kg Muscle Provisional MRLs expire on 1.1.2001
50 μg/kg Fat
25 μg/kg Liver
20 μg/kg Kidney
Doramectin Doramectin Deer, inclusing reindeer 20 μg/kg Muscle Provisional MRLs expire on 1.7.2001
100 μg/kg Fat
50 μg/kg Liver
30 μg/kg Kidney]
Moxidectin Moxidectin Equidae 50 μg/kg Muscle Provisional MRLs expire on 1 January 2000
500 μg/kg Fat
100 μg/kg Liver
50 μg/kg Kidney

[F62.4. Agents acting against protozoa U.K.

2.4.1. Carbanilides U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Imidocarb Imidocarb Bovine, ovine 300 μg/kg Muscle Provisonal MRLs expire on 1.1.2002
50 μg/kg Fat
2 000 μg/kg Liver
1 500 μg/kg Kidney
50 μg/kg Milk
[F192.4.2. Quinazolone derivatives U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Halofuginone Halofuginone Bovine 10 μg/kg Muscle Provisional MRL's expire on 1.1.2001
25 μg/kg Fat
30 μg/kg Liver
30 μg/kg Kidney]
[F72.4.3. Triazinetrione derivatives U.K.
a

[F37Provisional MRLs expire on 1 July 2006 . Not for use in animals from which milk is produced for human consumption.] ]

Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Toltrazuril Toltrazuril sulfone Porcine 100 μg/kg Muscle Provisional MRLs expire on 1.1.2001
150 μg/kg Skin and fat
500 μg/kg Liver
250 μg/kg Kidney
[F37Toltrazuril a Toltrazuril sulfone Bovine 100 μg/kg Muscle
150 μg/kg Fat
500 μg/kg Liver
250 μg/kg Kidney]

Textual Amendments

[F382.4.4. Other anti-protozoal agents U.K.
Pharmacologically active substance(s) Marker residue Animal species MRL Target tissues Other provisions
Amprolium Amprolium Chicken, turkey 200 μg/kg Muscle Provisional MRLs expire on 1.1.2002
200 μg/kg Skin and fat
200 μg/kg Liver
400 μg/kg Kidney
1 000  μg/kg Eggs] ]

Textual Amendments

3. Agents acting on the nervous system U.K.

3.2. Agents acting on the autonomic nervous system U.K.

3.2.1. β 2 sympathomimetic agents U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Clenbuterol hydrochloride Clenbuterol Bovine 0,1 μg/kg Muscle Provisional MRLs expire on 1 July 2000
Indication: solely for tocolysis in parturient cows 0,5 μg/kg Liver
0,5 μg/kg Kidney
0,05 μg/kg Milk
Equidae 0,1 μg/kg Muscle
Indications: tocolysis and the treatment of respiratory ailments 0,5 μg/kg Liver
0,5 μg/kg Kidney
[F63.2.2. Anti-adrenergics U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Carazolol Carazolol Bovine 5 μg/kg Muscle Provisional MRLs expire on 1.1.2000
5 μg/kg Fat
15 μg/kg Liver
15 μg/kg Kidney
1 μg/kg Milk]

5. Anti-inflammatory agents U.K.

5.1. Nonsteroidal anti-inflammatory agents U.K.

5.1.1. Arylpropionic acid derivative U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Carprofen Carprofen Bovine 500 μg/kg Muscle Provisional MRLs expire on 1 January 2000
500 μg/kg Fat
1 000  μg/kg Liver
1 000  μg/kg Kidney
Equidae 50 μg/kg Muscle
100 μg/kg Fat
1 000  μg/kg Liver
1 000  μg/kg Kidney
5.1.2. Enolic acid derivates U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Meloxicam Meloxicam Bovine 25 μg/kg Muscle Provisional MRLs expire on 1 January 2000
60 μg/kg Liver
35 μg/kg Kidney
[F115.1.3. Pyrazolone derivatives U.K.
Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
[F12Metamizole 4-Methylaminoantipyrin Bovine, porcine, equidae 200 μg/kg Muscle

Provisional MRLs expire on 1.7.2003 .

Not for use in animals from which milk is produced for human consumption

200 μg/kg Fat
200 μg/kg Liver
200 μg/kg Kidney] ]

[F396. Agents acting on the reproductive system U.K.

6.1. Progestogens U.K.

Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Altrenogest Altrenogest Porcine 3 μg/kg [F40Skin and fat] [F40Provisional MRLs expire on 1.1.2005 ; for zootechnical use only]
3 μg/kg Liver
3 μg/kg Kidney
Equidae 3 μg/kg Fat
3 μg/kg Liver
3 μg/kg Kidney
[F41Flugestone acetate Flugestone acetate Ovine, caprine 0,5 μg/kg Muscle Provisional MRLs expire on 1.1.2008 ; for therapeutic or zootechnical use only
0,5 μg/kg Fat
0,5 μg/kg Liver
0,5 μg/kg Kidney
Norgestomet Norgestomet Bovine 0,5 μg/kg Muscle Provisional MRLs expire on 1.1.2008 ; for therapeutic or zootechnical use only
0,5 μg/kg Fat
0,5 μg/kg Liver
0,5 μg/kg Kidney
0,15 μg/kg Milk] ]

Textual Amendments

Textual Amendments

[F47. Corticoids U.K.

7.1. Glucocorticoids U.K.

Pharmacologically active substance(s) Marker residue Animal species MRLs Target tissues Other provisions
Methylprednisolone Methylprednisolone Bovine 10 μg/kg Muscle Provisional MRLs expire on 1.7.2001 . Not for use in animals from which milk is produced for human consumption
10 μg/kg Fat
10 μg/kg Liver
10 μg/kg Kidney] ]

Back to top

Options/Help

Print Options

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.

Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.

Close

See additional information alongside the content

Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.

Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the EU Official Journal
  • lists of changes made by and/or affecting this legislation item
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

Timeline of Changes

This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.

The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.

For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.

Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources

The data on this page is available in the alternative data formats listed: